Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;31(4):811-6.
doi: 10.1007/s00345-011-0684-1. Epub 2011 May 19.

The predictive value of immunohistochemical markers in untreated Wilms' tumour: are they useful?

Mazen A Ghanem  1 , Theo H van der Kwast, W M Molenaar, Manal A Safan, Rien J Nijman, Gert Jan van Steenbrugge
Affiliations

The predictive value of immunohistochemical markers in untreated Wilms' tumour: are they useful?

Mazen A Ghanem et al. World J Urol. 2013 Aug.

Abstract

Purpose: This study reevaluates the potential role of different tumour markers as prognostic indicators in untreated nephroblastoma.

Methods: Expression of a broad panel of tumour markers was investigated by means of immunohistochemical analysis in 43 WT patients. Patients were treated by radical nephrectomy and had a mean follow-up of 11.9 years.

Results: Generally, all the tumour markers studied were expressed in normal kidney tissue and at variable levels in the three cell types of WT (blastema, epithelium and stroma). Immunoreactive blastemal (Bcl-X, Bcl-2 and CD44s) and epithelial (Bcl-X, Bcl-2 and MIB-1) cells were present in the majority of tumours. No correlation was found between their expression and pathological stages. Univariate analysis showed that blastemal WT-1, TGF-α, VEGF, MIB-1 and p27 Kip1 were indicative for clinical progression. In a multivariate analysis, WT-1 protein expression by blastemal cells was an independent prognostic marker for clinical progression.

Conclusions: The blastemal WT-1, TGF-α, VEGF, MIB-1 and p27Kip1 expression correlate with clinical progression in untreated nephroblastoma. Therefore, their expression may be of value in identifying patients with a high propensity to develop distant metastases.

PubMed Disclaimer

References

    1. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms’ tumour. Cancer. 1978;41:1937–1948. doi: 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U. - DOI - PubMed
    1. Breslow NB, Churchill G, Beckwith JB, Fernbach DJ, Otherson HB, Tefft M, D’Angio GJ. Prognosis for Wilms’ tumour patients with nonmetastatic disease at diagnosis: results of the Second National Wilms’ Tumour Study. J Clin Oncol. 1985;3:521–531. - PubMed
    1. Lemerle J, Voute PA, Tournade MF, Delemarre JF, Jereb B, Ashtrom L, Flamant R, Gerard-Marchant R. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms’ tumour: preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (SIOP) Cancer. 1976;38:647–654. doi: 10.1002/1097-0142(197608)38:2<647::AID-CNCR2820380204>3.0.CO;2-C. - DOI - PubMed
    1. Burger D, Feickert HJ, Mildenberger H. Current status of nephroblastoma treatment. Malignant neoplasms in childhood. New York: Karger; 1986. pp. 224–242.
    1. Lemerle J, Voûte PA, Tournade MF, Rodary C, Delemarre JF, Sarrazin D, Burgers JM, Sandstedt B, Mildenberger H, Carli M, Jereb B, Moorman-Voestermans CGM. Effectiveness of preoperative chemotherapy in Wilms’ tumour: Results of an international Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol. 1983;10:604–609. - PubMed

Publication types

MeSH terms